148 related articles for article (PubMed ID: 8603261)
1. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection.
Klausner JD; Makonkawkeyoon S; Akarasewi P; Nakata K; Kasinrerk W; Corral L; Dewar RL; Lane HC; Freedman VH; Kaplan G
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Mar; 11(3):247-57. PubMed ID: 8603261
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.
Tramontana JM; Utaipat U; Molloy A; Akarasewi P; Burroughs M; Makonkawkeyoon S; Johnson B; Klausner JD; Rom W; Kaplan G
Mol Med; 1995 May; 1(4):384-97. PubMed ID: 8521296
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection.
Gori A; Rossi MC; Trabattoni D; Marchetti G; Fusi ML; Molteni C; Clerici M; Franzetti1 F
J Infect Dis; 2000 Aug; 182(2):639-40. PubMed ID: 10915104
[No Abstract] [Full Text] [Related]
4. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA
N Engl J Med; 1997 May; 336(21):1487-93. PubMed ID: 9154767
[TBL] [Abstract][Full Text] [Related]
5. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Reyes-Terán G; Sierra-Madero JG; Martínez del Cerro V; Arroyo-Figueroa H; Pasquetti A; Calva JJ; Ruiz-Palacios GM
AIDS; 1996 Nov; 10(13):1501-7. PubMed ID: 8931784
[TBL] [Abstract][Full Text] [Related]
6. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus.
Haslett P; Hempstead M; Seidman C; Diakun J; Vasquez D; Freedman VH; Kaplan G
AIDS Res Hum Retroviruses; 1997 Aug; 13(12):1047-54. PubMed ID: 9264292
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.
Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C
J Infect Dis; 2001 Jan; 183(2):343-346. PubMed ID: 11120935
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide inhibits the replication of human immunodeficiency virus type 1.
Makonkawkeyoon S; Limson-Pobre RN; Moreira AL; Schauf V; Kaplan G
Proc Natl Acad Sci U S A; 1993 Jul; 90(13):5974-8. PubMed ID: 8327469
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide for the treatment of AIDS-associated wasting.
Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PA; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1345-55. PubMed ID: 11018854
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.
Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N
J Infect Dis; 1999 Jul; 180(1):61-7. PubMed ID: 10353862
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide and HIV: several possible uses.
Smith D
AIDS Treat News; 1995 Apr; (no 221):1-4. PubMed ID: 11362402
[TBL] [Abstract][Full Text] [Related]
12. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines.
Marriott JB; Cookson S; Carlin E; Youle M; Hawkins DA; Nelson M; Pearson M; Vaughan AN; Gazzard B; Dalgleish AG
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1625-31. PubMed ID: 9430254
[TBL] [Abstract][Full Text] [Related]
13. The thalidomide comeback.
HIV Hotline; 1998 May; 8(2):7, 9, 15. PubMed ID: 11365364
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide pros and cons.
Am J Nurs; 1998 Apr; 98(4):63. PubMed ID: 9556688
[No Abstract] [Full Text] [Related]
15. Thalidomide use is associated with weight gain in HIV-1-positive clients.
Sharp M; Getty J; Klausner JD
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(5):392. PubMed ID: 9342262
[No Abstract] [Full Text] [Related]
16. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia.
Shannon E; Noveck R; Sandoval F; Kamath B; Kearney M
Transl Res; 2007 Nov; 150(5):275-80. PubMed ID: 17964516
[TBL] [Abstract][Full Text] [Related]
17. Effect of thalidomide in patients with chronic heart failure.
Gullestad L; Semb AG; Holt E; Skårdal R; Ueland T; Yndestad A; Frøland SS; Aukrust P
Am Heart J; 2002 Nov; 144(5):847-50. PubMed ID: 12422154
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis.
Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G
J Infect Dis; 2000 Mar; 181(3):954-65. PubMed ID: 10720518
[TBL] [Abstract][Full Text] [Related]
19. Anticytokine approaches to the treatment of anorexia and cachexia.
Haslett PA
Semin Oncol; 1998 Apr; 25(2 Suppl 6):53-7. PubMed ID: 9625384
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide-based treatment for HIV-associated multiple myeloma: a case report.
Aboulafia DM
AIDS Read; 2003 Aug; 13(8):383-9. PubMed ID: 14524324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
